HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

November 22nd 2024

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

November 20th 2024

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

Dr Rimm on the Utility and Shortcomings of HER2 IHC Testing in Breast Cancer

November 18th 2024

David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.

Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain Metastases

November 15th 2024

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer

November 13th 2024

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

Dr Feldman on the Recognition of Racial Disparities in Breast Cancer

November 7th 2024

Sheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.

Neoadjuvant SHR-A1811 Plus Pyrotinib Shows Preliminary Efficacy, Safety in HER2+ Breast Cancer

November 4th 2024

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer

October 24th 2024

Sung Gwe Ahn, MD, PhD, discusses survival outcomes with ovarian function suppression-based endocrine therapy based on the HERA trial in HR-positive, HER2-positive breast cancer.

Dr Rimm on Limitations With IHC Testing in HER2-Low and HER2-Ultralow Breast Cancer

October 23rd 2024

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dr Gluz on the Rationale for the WSG-TP-II Trial in HR+/HER2+ Early Breast Cancer

October 15th 2024

Oleg Gluz, MD, discusses the rationale for investigating neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.

Neoadjuvant Pertuzumab Biosimilar Plus Trastuzumab/Docetaxel Meets pCR End Point in HER2+ Breast Cancer

October 7th 2024

HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.

Long-Term Data Add to Prognostic Value of TILs in Treatment De-Escalation in Early HER2+ Breast Cancer

October 4th 2024

Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.

DCISionRT Biosignature Identifies Residual Recurrence Risk in HER2(3+) Breast Cancer

October 2nd 2024

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast Cancer

October 2nd 2024

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

De-Escalated Neoadjuvant Treatment Does Not Compromise Survival Outcomes in HR+/HER2+ Early Breast Cancer

October 2nd 2024

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Dr Gluz on Survival Outcomes With De-Escalated Neoadjuvant Regimens in HR+/HER2+ Early Breast Cancerer

September 27th 2024

Oleg Gluz, MD, discusses data from the WSG-TP-II trial of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

September 26th 2024

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer

September 19th 2024

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.